Aulos Bioscience
PrivateLast Round
Series A
Extension
Aug 1, 2023
Total Funding Raised
$60M
Company Overview
Aulos Bioscience operates in Healthcare & Life Sciences and is based in Larkspur, California. Its latest recorded funding round was a Series A Extension round in August 2023.
Aulos Bioscience is a biotechnology company that develops innovative immuno-oncology therapeutics and IL-2 targeting antibodies to direct patients' immune systems toward killing solid tumor cells.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aulos Bioscience Comparables
Compare Aulos Bioscience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Synthekine | 85% | |
| Anaveon | 84% | |
| Anwita Biosciences Inc. | 80% |
For institutional investors. Book with your work email.
Aulos Bioscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Aug 1, 2023 | ||||
| Series A | Jan 8, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Aulos Bioscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Apple Tree Partners | Series A, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors grew 174% MoM, reaching 6K.
- Nov 12, 2025
Developing a human monoclonal antibody targeting regulatory T cells.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 13, 2026
Aulos Bioscience, Inc. plans to present Phase 2 data for imneskibart with avelumab in checkpoint inhibitor-refractory adenocarcinoma non-small cell lung cancer at ESMO Congress 2026 in Oct '26.
For institutional investors. Book with your work email.
Aulos Bioscience Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Aulos Bioscience's valuation, stock price, and market status.
Is Aulos Bioscience a public or private company?
Aulos Bioscience is a private company.
What is the current stock price of Aulos Bioscience?
Aulos Bioscience is a private company, so its shares have no public market price. Caplight tracks Aulos Bioscience's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Aulos Bioscience worth (valuation)?
Valuation information for Aulos Bioscience is not publicly available.
Can I buy Aulos Bioscience stock?
Aulos Bioscience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Aulos Bioscience's last funding round?
Aulos Bioscience's most recent funding round was Series A Extension on August 1, 2023.
Who are the main investors in Aulos Bioscience?
Key investors in Aulos Bioscience include Apple Tree Partners.
Will Aulos Bioscience IPO soon?
No public IPO plans have been announced for Aulos Bioscience.
How can I track Aulos Bioscience secondary market activity?
Caplight tracks bids, offers, and trades in Aulos Bioscience's shares on secondary markets.